Alexion and activist investor Elliott Management are putting their differences aside.
The two parties have agreed to “work collaboratively” to find a new member for Alexion’s board, they said late Tuesday. Alexion had announced back in November that it was looking to fill an open seat.
The agreement follows a December report that Elliott had built up a stake in the rare-disease drugmaker and was looking for a bigger effort from the company’s leaders to boost share prices. The fund also wanted to see more biotech experience on Alexion’s slate of directors, according to The New York Times—particularly now that Ludwig Hantson, the former helmsman of Baxalta, had filled key leadership positions with his pharma peers.
“This agreement is in line with our ongoing efforts to maintain active and constructive dialogue with all of our shareholders and to identify a new board member with a proven track record of building value,” Chairman David Brennan said in a statement.
At least one analyst likely wasn’t surprised to see activists jump into the mix at Alexion, which spent 2017 working to find its footing after key leaders departed amid a late-2016 sales-fraud investigation. Leerink Partners’ Geoffrey Porges has called the biotech “one of the rare, once or twice per decade, activist investment situations in the biopharmaceutical industry.”
Elliott, though, seems to like what it’s seen over the last couple of months from Hantson, whose moves have included hundreds of layoffs and a headquarters relocation. “We are encouraged by actions taken under Ludwig’s leadership to improve financial performance and reset Alexion’s strategy,” a spokesperson said in a statement.
By Carly Helfand
Source: Fierce Pharma
In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).
In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.
